Cargando…
Calcipotriol/betamethasone foam for proactive management of plaque psoriasis: four case reports
Psoriasis is a chronic inflammatory disease affecting about 100 million people worldwide. Around 80% of patients can be treated with topical agents, most commonly corticosteroids and vitamin D analogues. A topical foam formulation of calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) (...
Autores principales: | Apalla, Zoe, Perrussel, Marc, Rallis, Efstathios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioExcel Publishing Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267161/ https://www.ncbi.nlm.nih.gov/pubmed/35864998 http://dx.doi.org/10.7573/dic.2022-4-3 |
Ejemplares similares
-
Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam For Scalp Psoriasis
por: Anderko, Marian, et al.
Publicado: (2019) -
Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: case series and review of the literature
por: Pinter, Andreas, et al.
Publicado: (2018) -
Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris
por: Vakirlis, Efstratios, et al.
Publicado: (2008) -
Efficacy and Safety of Different Formulations of Calcipotriol/Betamethasone Dipropionate in Psoriasis: Gel, Foam, and Ointment
por: Rudnicka, Lidia, et al.
Publicado: (2021) -
Editorial: fixed‐dose combination calcipotriol/betamethasone dipropionate foam in the treatment of patients with psoriasis
por: Lebwohl, M., et al.
Publicado: (2021)